GGrantIndex
← Search

Small Animal Imaging Shared Resource (SAISR)

$274,503P30FY2023CANIH

University Of California Los Angeles, Los Angeles CA

Investigators

Linked publications, trials & patents

Trial NCT07339085Trial NCT07276438Trial NCT07242365Trial NCT06650163Trial NCT06568016Trial NCT06113016Trial NCT05595499Trial NCT04205838Trial NCT04201873Trial NCT04185311Trial NCT04119024Trial NCT04106362Trial NCT04069923Trial NCT04069910Trial NCT04050215Trial NCT04007029Trial NCT03996850Trial NCT03970252Trial NCT03953157Trial NCT03904251Trial NCT03902951Trial NCT03892720Trial NCT03830918Trial NCT03825796Trial NCT03745690Trial NCT03732950Trial NCT03732352Trial NCT03672773Trial NCT03623854Trial NCT03618134Trial NCT03603223Trial NCT03601455Trial NCT03596710Trial NCT03582774Trial NCT03582475Trial NCT03541850Trial NCT03515577Trial NCT03506802Trial NCT03425461Trial NCT03411070Trial NCT03368547Trial NCT03319342Trial NCT03240861Trial NCT03202472Trial NCT03128619Trial NCT03025139Trial NCT03014804Trial NCT02940262Trial NCT02928510Trial NCT02925351Trial NCT02919332Trial NCT02902757Trial NCT02888301Trial NCT02881242Trial NCT02880020Trial NCT02879994Trial NCT02830165Trial NCT02816879Trial NCT02775292Trial NCT02756130Trial NCT02701153Trial NCT02688348Trial NCT02683200Trial NCT02672033Trial NCT02597894Trial NCT02575027Trial NCT02451865Trial NCT02336763Trial NCT02310594Trial NCT02296229Trial NCT02280161Trial NCT02263898Trial NCT02176902Trial NCT02070406Trial NCT02049593Trial NCT02048020Trial NCT02015559Trial NCT01912820Trial NCT01013285Trial NCT01005472Trial NCT00999557Trial NCT00998010Trial NCT00985192Trial NCT00955591Trial NCT00882765Trial NCT00880542Trial NCT00769470Trial NCT00706615Trial NCT00685516Trial NCT00616642Trial NCT00612066Trial NCT00601289Trial NCT00601094Trial NCT00521209Trial NCT00509431Trial NCT00471887Trial NCT00450567Trial NCT00444223Trial NCT00352001Trial NCT00349167

Abstract

SMALL ANIMAL IMAGING SHARED RESOURCE (SAISR) ABSTRACT The Small Animal Imaging Shared Resource (SAISR) provides instrumentation, training, and expert support for imaging studies conducted by UCLA Jonsson Comprehensive Cancer Center (JCCC) investigators. Major technologies and services include micro-positron emission tomography (microPET), invented at SAISR, micro- computed tomography (microCT), optical imaging (bioluminescence, fluorescence and Cerenkov), autoradiography imaging, and routine production of small molecule radiochemistry and peptide/protein radiolabeling. SAISR has a biomedical cyclotron, biomolecule radiolabeling facility, and a fully equipped radiochemistry facility with state-of-the-art radiosynthesizers specifically designed to support PET imaging. Three specific aims support the SAISR objective of providing investigators with technical imaging expertise and facilitating the design, execution, and analysis of small animal imaging studies. Aim 1: to provide and support state-of-the-art small animal imaging technologies; Aim 2: to provide routine radiochemistry and radiolabeling production services; and Aim 3: to provide investigators with scientific support and training in radiochemistry, preclinical imaging, and image analysis. Monthly two-hour training sessions educate users on the latest imaging technologies and approaches, including topics on instrumentation basics, imaging biology, imaging procedures, and safety protocols. Examples of SAISR impact in the prior project period include SAISR support for David Nathanson, PhD (CMINT) in developing novel combination therapies to target tumor metabolism in glioblastoma multiforme (GBM). PET/CT imaging of rapid changes in GBM glucose utilization by [18F]FDG, a biomarker of glycolysis, effectively predict therapeutic responses in vivo and is currently being tested in a clinical trial (NCT03732352). PET and MRI imaging enabled a large inter-programmatic team led by Robert Prins, PhD (CMINT/TI) to differentiate inflammatory responses in GBM by PET from other sources of contrast-enhancement seen by MRI. The combination of these two imaging modalities distinguished tumor progression from pseudoprogression in immunotherapy. In a collaboration between SAISR and JCCC Molecular Screening Shared Resource (MSSR), an inter-programmatic team led by Caius Radu, MD (CMINT) developed a combination therapy targeting deoxycytidine kinase (dCK) using [18F]FAC PET to assess the pharmacodynamics of novel dCK inhibitors. Follow-on PET studies showed that dCK contributes to radiation resistance in cancer. From 2013 – 2018, SAISR supported projects from 42 JCCC members in all six Programs, representing 84% of SAISR usage. Of this, 53% of JCCC users had peer-reviewed funding. This resulted in 136 publications, with 73 (54%) in high-impact (IF ≥10, or field leading) journals. The SAISR is preparing to submit an NIH shared instrumentation grant for a GNEXT PET/CT instrument, with the highest sensitivity currently available and based on technology invented by SAISR Director Arion Chatziioannou, PhD.

View original record on NIH RePORTER →